Cryo Cell International Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Cryo Cell International Inc in the third quarter 2026?
Due to the lack of equity, it was not possible to calculate Cryo Cell International Inc 's return on equity (ROE) in its third quarter 2026

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Aug 31 2026) III. Quarter	(May 31 2026) II. Quarter	(Feb 28 2026) I. Quarter	(Nov 30 2025) IV. Quarter	(Aug 31 2025) III. Quarter
Y / Y Equity Change	-	-	-	-	-
Y / Y Net Income Change	69.53 %	55.88 %	-83.35 %	-	-28.74 %
Net Income (TTM) in Millions	-2	-2	-3	-2	0
Return On Equity (TTM)	-	-	-	-	-
CCEL's Total Ranking	#	#	#	#	#
Equity (TTM) in Millions	-16	-18	-18	-19	-15
Seq. Equity Change	-	-	-	-	-
Seq. Net Income Change	129.09 %	1077.27 %	-	-	110.64 %

Back to CCEL Management Effectiveness >> CCEL's 5 Years Annual ROE >> Compare CCEL ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Equity Statistics
High	Average	Low
0 %	0 %	0 %

CCEL Annual Return On Equity	(Nov 30 2025) 2025	(Nov 30 2024) 2024	(Nov 30 2023) 2023	(Nov 30 2022) 2022	(Nov 30 2021) 2021
Total Equity in Millions	-19	-13	-11	-2	4
Y / Y Equity Change	-	-	-	-	-
Net Income in Millions	-2	0	-10	3	2
Y / Y Net Income Change	-	-	-	33.02 %	-42.52 %
Return On Equity	-	-	-	-	49.79 %

Back to CCEL Management Effectiveness >> CCEL's 5 Years Annual ROE >> Compare CCEL ROE to its Competitors

Annual Roe Comment

Despite deterioration in net income, company improved ROE to in 2025, company improved ROE to 49.79 % compared to the prior year.

More Return On Equity Ratios
Healthcare Facilities Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CCEL's' Return on Equity at Yahoo Finance
CCEL's Roe Ratio versus Healthcare Facilities Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CCEL's Competitors
Subscribers only: Roe for Cryo Cell International Inc 's Suppliers
Subscribers only: Return On Equity for CCEL's Customers

Companies with similar Return On Equity at Aug 31 2026, within Healthcare Sector	ROE
Transmedics Group Inc	28.74 %
Acadia Pharmaceuticals Inc	28.03 %
Pro dex Inc	26.91 %
Sotera Health Company	26.41 %
Pacs Group Inc	25.65 %
Standard Biotools Inc	25.58 %
Resmed Inc	25.50 %
Bioventus Inc	24.60 %
Encompass Health Corporation	24.08 %
Iradimed Corporation	23.90 %
Corcept Therapeutics Inc	22.88 %
Msa Safety Inc	21.79 %
Lantheus Holdings Inc	21.72 %
Iqvia Holdings Inc	21.40 %
Denali Therapeutics Inc	21.40 %
West Pharmaceutical Services Inc	21.08 %
Brightspring Health Services Inc	20.31 %
Healthcare Services Group Inc	20.22 %
Vertex Pharmaceuticals Inc	20.08 %
Ge Healthcare Technologies Inc	20.04 %
Neurocrine Biosciences Inc	19.74 %
Ani Pharmaceuticals Inc	19.70 %
Johnson and Johnson	19.55 %
Pediatrix Medical Group Inc	17.28 %
Kiniksa Pharmaceuticals International Plc	17.27 %
Krystal Biotech Inc	17.02 %
Intuitive Surgical Inc	16.99 %
Ensign Group Inc	16.62 %
Lemaitre Vascular Inc	15.81 %
Stryker Corp	15.61 %

Date modified: 2026-10-10T04:25:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.